More info…
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover’s list of the “Top 10 Most Interesting Neuroscience Projects to Watch.”
September 1, 2010 By Leave a Comment
Naurex announces GLYX-13 molecule recognized in Top 10 to Watch” list for depression treatment
Speak Your Mind
You must be logged in to post a comment.